TY - JOUR
T1 - Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria
AU - Morgan, Matt
AU - Cooke, Andrew
AU - Rogers, Laura
AU - Adams-Huet, Beverley
AU - Khan, David A.
N1 - Funding Information:
Funded by General Clinical Research Center Unites States Public Health Service grant M01–RR00633 and Clinical and Translational Science Award grant UL1-TR001105 .
Funding Information:
Conflicts of interest: M. Morgan has received research support from the National Institutes of Health (General Clinical Research Center). A. J. Cooke and B. Adams-Huet have received research support from the National Institutes of Health. D. A. Khan has received lecture fees from Genentech, Baxter, and Merck. L. Rogers declares that she has no relevant conflicts of interest.
Publisher Copyright:
© 2014 American Academy of Allergy, Asthma & Immunology.
PY - 2014
Y1 - 2014
N2 - Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95% CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95% CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95% CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31% and 41% had ≥50% resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.
AB - Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95% CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95% CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95% CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31% and 41% had ≥50% resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.
KW - Antihistamine
KW - Chronic idiopathic urticaria
KW - Dapsone
KW - RCT
KW - Urticaria
UR - http://www.scopus.com/inward/record.url?scp=84925108209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925108209&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2014.06.004
DO - 10.1016/j.jaip.2014.06.004
M3 - Article
C2 - 25213055
AN - SCOPUS:84925108209
SN - 2213-2198
VL - 2
SP - 601
EP - 606
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 5
ER -